Jacob Rubens

Jacob (Jake) is the CEO of Quotient and an Origination Partner at Flagship Pioneering. He is a scientist entrepreneur and leads a team that founds, builds, and grows companies based on new biotechnology.

At Flagship, Jake co-founded Sana Biotechnology and Tessera Therapeutics, and launched Kaleido Biosciences. In addition to his role at Quotient, Jake is the chief innovation officer and founding chief scientific officer at Tessera, where he led research from 2018 through 2021. Previously, Jake was the head of innovation at Cobalt Biomedicine, where he co-invented and developed the company’s Fusosome platform prior to its merger with Sana Biotechnology.

Before joining Flagship, Jake received his PhD in microbiology from MIT, working in the Synthetic Biology Center with Professor Tim Lu with the support of a National Science Foundation Graduate Research Fellowship. At MIT, Jake invented gene circuits that allow engineered cells to do novel analog, digital, and hybrid computations, enabling the emerging field of ​“intelligent” cell therapies.